Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Probably they do not have enough cash to pay for the stock options , so they sold some stocks to pay for the acquiring of the stock options .
Over the last 10 years , I have lost about 70 % of my investment capital . I invested in both large and small companies in oil sector , gold sector , etc ...
Investment returns depend on the skill of each person . For me , I rather invest my money in OPK where Dr. Frost has about 40 % of his net worth invested in . I know that I will not get rich in OPK in the short term but long term ( 3 -5 years ) this stock should be fine .
OPK added into NASDAG Biotechnology index effective Dec 19 . Mutual funds and ETF will buy OPK , shorts will be in trouble
article on Yahoo Finance stating VBIV is very undervalue
I am a long term subscriber of The Oxford Investment newsletters . Today they sent email reiterate that OPK will be a ten -baggers stock . They also stated that OPK will be profitable in the year ahead .
We can expect OPK to gradually going up in stock price .
I think most likely OPK will be profitable in 2017
OPK price does not go up until they announce the launch of Rayaldee
My guess : OPK's revenue FY 2020 about $ 5 billions
sales from Rayaldee : $ 2 B
Sales from BRLI group : $ 2 B
Sales from 4 kscores , etc .. : $ 1 B
Total : $ 5B
Assuming a price/ sale ratio : 3
Market Cap : 5x3 = $ 15 B
Stock price : about $30 / share . Is this too conservative ?
I wonder what price OPK will reach if revenue from Rayaldee is $ 2 Billions / year .
Anyone know ?
I think this is good news . I added more shares today
What I like from OPK is the risk / reward ratio . The stock can go down by one dollar or two but on the upside it can be traded in the $ 30 range in a few years . I do not see any other stocks that can give me this kind of risk/ reward ratio .
In my opinion , OPK is undervalued at around $ 9 / share .
The revenue from the BRLI group is about $ 1 billion / year . If we take an average 3 X of Price / sale ratio for health care companies then the contribution from the BRLI group is about $ 3 Bilion/ 0.5 billion shares = $ 6 / share
The revenues from Rayaldee and others in the pipelines will make OPK worth much more than $9/share.
As a side note , there is a chance of only 20 % that the democrate party can take over the house in this election .
My guess is OPK will reach $12 by January 2017 , and about $ 16 by summer 2017
the shorts know that they have only a few months left to cover . Starting early 2017 substantial revenues of 4 k scores and Rayaldee will be coming in and they will loose the opportunity to cover their shorts .
From WS Journal , the average analysts price target for OPK is $16.40 .
That is a 75 % return for 12 months . Where else can you get this kind of return ?
OPK has very little downside risk and a huge upside potential
OPK is a stock with little downside risk and with a huge upward potential . The Oxford Communique investment newsletters recommended OPK as a minimum ten-bagger stock
OPK is one of the best stock to be in long term .
What I like in OPK is the risk / reward ratio .
The down side risk is minimal , it can go down by a few dollars but the upside reward is huge : most likely it will be a ten-bagger stock .
The only thing you need to do is : be patient
I think in 5 years OPK will be in the $ 50 to $ 75
In 10 years OPK will be in the $ 100-$ 300 . Due to the large number of outstanding shares the best it can reach is $ 300
Starting in January 2017 substantial revenues will be coming in from 4 kscores and Rayaldee . The shorts know that they have only a few months left to try to push the price lower . Now is the time to accumulate OPK at this ridiculous price
Anyone knows if Frost takes OPK private :
1) Does he have that capability ?
2) What price would he offer ?
There are both good and bad news for OPK .
The bad news is it sits around $ 10 for too long .
The good news is the mean analyst price for OPK is $ 15 , that is 50 % higher in 12 months .Where else can we invest to get this kind of return ?
I believe there are board members who have a few hundreds thousand shares bought at a few dollars / share . If Titan goes bankrupt , they will have major losses
Since OPK will be around $ 10 for may be 3-6 months , risk taking investors can sell some OPK funds to invest in more speculative stocks like AXDX , then sell AXDX at a gain and reinvest in OPK .That's what I am doing ..
OPK has very minimal downside risk but a huge upside potential . About 90 % of my non-retirement portfolio is in OPK
I received the newsletters by mail on August 3
I think OPK will reach at least $ 50 by year 2020
The August edition of the investment newsletters The Oxford Communique recommended OPK as a ten-bagger stock
OPK is a stock with a very favorable risk/reward ratio . It can go down by a few dollars at most but on the upside it can become a few hundreds dollars / share stock
In the newsletters they said that OPKO is working on drugs to treat cancer , Alzheimer , Parkinson , virus influenza ,...The CEO owns 186 million shares and is a regular investor in the stock...This is a vote of confidence in the firm .
OPK is recommended in the August newsletters The Oxford Communique as a ten-baggers stock.
Most likely the revenues of OPK will be about $ 5 billions in year 2020 . With a price-per -sale ratio of 7 , OPK will reach about $ 70 in 4 years
You are welcome
It is true . News from Uncltlzz
Rayaldee approved on 06/17/16
I bought 5000 shares this week . Will buy some more next week
Expect revenue $ 35 M for 2016 and $50 M for 2017 . Assume the profit percentage is 20 % . Thus earning will be $ 7M for 2016 and $10 M for 2017 .
Assuming a P/E ratio 50 : CDXC will be traded at $ 9 in 2016 and $13 in 2017 . Does this sound reasonable ?
If Niagen indeed can reverse the aging process , then this benefit alone can make CDXC become a 100 $ / share stock . Who does not want to get back his / her youth ?
I have only 28k shares of TITXF .
Does any retail investor have more than 500 k shares ?
Just want to know
OPK is a low risk company . Out of the present $ 1.3 billions revenues , about $ 1 billion come from the BRLI group and this group 's revenue increases about 20 % per year